The isolated capsular polysaccharide induces antibody protective against invasive infections by H. influenzae b. Maturation of responsiveness is slow such that infants are not protected. Several protein-coupled versions of the antigen are being tested for immunogenicity in early infancy. The relation of structure to immunogenicity is not completely defined, but all induce a booster-type antibody response with protective potential. Primary vaccination in infancy appears to mimic natural priming, activating clones of B lymphocytes that can later be restimulated by uncoupled polysaccharide. Prospects appear good for immunizing normal infants and also children with immunoregulatory defects predisposing to infection.